HC Wainwright Raises BioNTech (NASDAQ:BNTX) Price Target to $113.00

BioNTech (NASDAQ:BNTX) had its price target upped by analysts at HC Wainwright from $107.00 to $113.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 24.34% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. The Goldman Sachs Group reduced their price objective on BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 28th. JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research report on Friday, March 22nd. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. BMO Capital Markets reduced their target price on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, UBS Group dropped their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, BioNTech has an average rating of “Hold” and an average price target of $118.82.

BioNTech Trading Down 2.6 %

Shares of BNTX opened at $90.88 on Wednesday. The firm’s fifty day moving average is $90.50 and its two-hundred day moving average is $95.99. The stock has a market cap of $21.60 billion, a PE ratio of 22.06 and a beta of 0.25. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. BioNTech has a 52-week low of $85.21 and a 52-week high of $125.83.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a net margin of 24.26% and a return on equity of 4.60%. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $2.04 billion. Research analysts forecast that BioNTech will post -1.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the period. CWM LLC boosted its holdings in BioNTech by 657.6% in the fourth quarter. CWM LLC now owns 250 shares of the company’s stock valued at $26,000 after purchasing an additional 217 shares during the period. Frazier Financial Advisors LLC acquired a new position in BioNTech during the 4th quarter worth $30,000. Covestor Ltd purchased a new stake in BioNTech during the 3rd quarter worth about $32,000. Finally, First Horizon Advisors Inc. acquired a new stake in BioNTech in the 4th quarter valued at about $38,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.